Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4576MR)

This product GTTS-WQ4576MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4576MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9451MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ8138MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ13995MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10693MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ1547MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13008MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ11103MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ5283MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW